PLA2G7 Antikörper (AA 176-415)
Kurzübersicht für PLA2G7 Antikörper (AA 176-415) (ABIN6719581)
Target
Alle PLA2G7 (Lp-PLA2) Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 176-415
-
Verwendungszweck
- Anti-PAFAH/PLA2G7 Antibody Picoband®
-
Kreuzreaktivität (Details)
- No cross-reactivity with other proteins.
-
Produktmerkmale
- Anti-PAFAH/PLA2G7 Antibody Picoband® (ABIN6719581). Tested in ELISA, WB applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
-
Aufreinigung
- Immunogen affinity purified.
-
Immunogen
- E. coli-derived human PAFAH recombinant protein (Position: A176-N415).
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
Western blot, 0.1-0.5 μg/mL
ELISA (Cap), 1-5 μg/mL
1. Claud, E. C., Li, D., Xiao, Y., Caplan, M. S., Jilling, T. Platelet-activating factor regulates chloride transport in colonic epithelial cell monolayers. Pediat. Res. 52: 155-162, 2002. 2. Jang, Y., Kim, O. Y., Koh, S. J., Chae, J. S., Ko, Y. G., Kim, J. Y., Cho, H., Jeong, T.-S., Lee, W. S., Ordovas, J. M., Lee, J. H. The val279phe variant of the lipoprotein-associated phospholipase A2 gene is associated with catalytic activities and cardiovascular disease in Korean men. J. Clin. Endocr. Metab. 91: 3521-3527, 2006. 3. Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.Lancet 375: 1536-1544, 2010. -
Kommentare
-
Tested Species: In-house tested species with positive results. Other applications have not been tested. Optimal dilutions should be determined by end users.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.
-
Konzentration
- 500 μg/mL
-
Buffer
- Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.05 mg NaN3.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
-
Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.
-
-
- PLA2G7 (Lp-PLA2) (Lipoprotein-Associated phospholipase A2 (Lp-PLA2))
-
Andere Bezeichnung
- PLA2G7
-
Hintergrund
-
Synonyms: Platelet-activating factor acetylhydrolase, PAF acetylhydrolase, 1-alkyl-2-acetylglycerophosphocholine esterase, 2-acetyl-1-alkylglycerophosphocholine esterase, Group-VIIA phospholipase A2, gVIIA-PLA2, LDL-associated phospholipase A2, LDL-PLA (2), PAF 2-acylhydrolase, PLA2G7, PAFAH
Tissue Specificity: Plasma.
Background: Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet-activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme that in humans is encoded by the PLA2G7 gene. Lp-PLA2 is a 45- kDa protein of 441 amino acids. It is one of several PAF acetylhydrolases. In the blood it travels mainly with low-density lipoprotein (LDL). Less than 20 % is associated with high-density lipoprotein HDL. It is an enzyme produced by inflammatory cells and hydrolyzes oxidized phospholipids in LDL. Lp-PLA2 is platelet-activating factor (PAF) acetylhydrolase, a secreted enzyme that catalyzes the degradation of PAF to inactive products by hydrolysis of the acetyl group at the sn-2 position, producing the biologically inactive products LYSO-PAF and acetate.
-
Molekulargewicht
- 50 kDa
-
Gen-ID
- 7941
-
UniProt
- Q13093
-
Pathways
- Peptide Hormone Metabolism
Target
-